Right after Takeda deal, Denali medical director heads to rival Alkahest

exit
Jonas Hannestad will head Alkahest's Alzheimer's and Parkinson's programs. (Pixabay)

Hard on the heels of a big IPO and a lucrative deal with Takeda, one of Denali’s top executives is leaving the company to join anti-aging startup Alkahest.

Jonas Hannestad, M.D., Ph.D.—who is also adjunct assistant professor of psychiatry at Yale School of Medicine—is taking up the role of senior medical director at Alkahest, moving on from the medical director role he had at South San Francisco-based Denali.

Hannestad’s specialty is neurosciences, including PET imaging in neuroinflammatory and other neurological disorders, which is a good fit for his role at Alkahest heading up clinical programs in Alzheimer’s and Parkinson’s disease. The company is looking at using infusions of plasma from young donors, thought to be rich in soluble factors that it hopes will help counteract nerve cell degeneration.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

While still in early-stage development, toward the end of last year Alkahest reported preliminary data in nine patients that suggested improvement in functional activity in patients with mild-to-moderate Alzheimer’s.

Hannestad is leaving Denali at a time when its star seems to be in the ascendency. His departure comes shortly after the biotech signed a partnership deal with Takeda, including $150 million in upfront cash and stock, that is focusing on three candidates for neurodegenerative diseases based on Denali’s ATV delivery tech that ushers drugs across the blood-brain barrier.

That deal came shortly after it raised $250 million in an IPO last month, although as it stands just one of its programs—LRRK2 inhibitor DNL201 for Parkinson’s—has reached the clinical trials stage.

Hannestad is one of two new hires for Alkahest along with Karl Trass, who joins the San Carlos biotech from Tobira Therapeutics where he was vice president, regulatory affairs prior to Tobira's acquisition by Allergan in 2016.

Alkahest chief operating officer Helen Jenkins said the new appointments will expand the development team at the company “as we work to bring innovative medicines to patients with Alzheimer's disease, Parkinson's disease and other serious diseases of aging.”

Suggested Articles

Janssen is planning its first completely virtual clinical trial, using personal smartphones and wearable devices with no in-person site visits.

Sensyne Health aims to bring its AI tools to America, and it’s enlisting IT giant Cognizant and data infrastructure specialist Agorai to help.

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.